Contribution of myelin autoantigen citrullination to T cell autoaggression in the central nervous system

Journal of Immunology

Volumn 184, Issue 6, 2010, Pages 2839-2846

  Carrillo Vico, Antonio ^a,b   Leech, Melanie D ^a   Anderton, Stephen M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; AUTOANTIGEN; CITRULLINE; EPITOPE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN ARGININE DEIMINASE; ARGININE DEIMINASE; GLYCOPROTEIN; HYDROLASE; LYMPHOCYTE ANTIGEN RECEPTOR; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35 55); MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); NERVE PROTEIN; PEPTIDE FRAGMENT; PEPTIDYLARGININE DEIMINASE TYPE IV; PROTEIN-ARGININE DEIMINASE;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL TRANSFER; CENTRAL NERVOUS SYSTEM; CROSS REACTION; DISEASE EXACERBATION; ENZYME INDUCTION; IMMUNIZATION; LYMPHOCYTE SUBPOPULATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CITRULLINE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GLYCOPROTEINS; HYDROLASES; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL;

EID: 77951901491     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903639     Document Type: Article

References (58)

1. Uy, R., and F. Wold. 1977. Posttranslational covalent modification of proteins. Science 198: 890-896.
2. Doyle, H. A., R. J. Gee, and M. J. Mamula. 2007. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity 40: 131-137.
3. Makrygiannakis, D., E. af Klint, I. E. Lundberg, R. Löfberg, A. K. Ulfgren, L. Klareskog, and A. I. Catrina. 2006. Citrullination is an inflammation-dependent process. Ann. Rheum. Dis. 65: 1219-1222.
4. Chou, J., J. J. Chen, M. Gross, and B. Roizman. 1995. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc. Natl. Acad. Sci. USA 92: 10516-10520.
5. Anderton, S. M. 2004. Post-translational modifications of self antigens: implications for autoimmunity. Curr. Opin. Immunol. 16: 753-758.
6. Kim, J. K., F. G. Mastronardi, D. D. Wood, D. M. Lubman, R. Zand, and M. A. Moscarello. 2003. Multiple sclerosis: an important role for posttranslational modifications of myelin basic protein in pathogenesis. Mol. Cell. Proteomics 2: 453-462.
7. Szekanecz, Z., L. Soós, Z. Szabó, A. Fekete, A. Kapitány, A. Végvári, S. Sipka, G. Szücs, S. Szántó, and G. Lakos. 2008. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets? Clin. Rev. Allergy Immunol. 34: 26-31.
8. Harauz, G., and A. A. Musse. 2007. A tale of two citrullines - structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem. Res. 32: 137-158.
9. Inagaki, M., H. Takahara, Y. Nishi, K. Sugawara, and C. Sato. 1989. Ca2+ -dependent deimination-induced disassembly of intermediate filaments involves specific modification of the amino-terminal head domain. J. Biol. Chem. 264: 18119-18127.
10. Chavanas, S., M. C. Méchin, R. Nachat, V. Adoue, F. Coudane, G. Serre, and M. Simon. 2006. Peptidylarginine deiminases and deimination in biology and pathology: relevance to skin homeostasis. J. Dermatol. Sci. 44: 63-72.
11. Vossenaar, E. R., T. R. Radstake, A. van der Heijden, M. A. van Mansum, C. Dieteren, D. J. de Rooij, P. Barrera, A. J. Zendman, and W. J. van Venrooij. 2004. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 63: 373-381.
12. Asaga, H., K. Akiyama, T. Ohsawa, and A. Ishigami. 2002. Increased and type II-specific expression of peptidylarginine deiminase in activated microglia but not hyperplastic astrocytes following kainic acid-evoked neurodegeneration in the rat brain. Neurosci. Lett. 326: 129-132.
13. Foulquier, C., M. Sebbag, C. Clavel, S. Chapuy-Regaud, R. Al Badine, M. C. Méchin, C. Vincent, R. Nachat, M. Yamada, H. Takahara, et al. 2007. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 56: 3541-3553.
14. Masson-Bessière, C., M. Sebbag, E. Girbal-Neuhauser, L. Nogueira, C. Vincent, T. Senshu, and G. Serre. 2001. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha-and beta-chains of fibrin. J. Immunol. 166: 4177-4184.
15. Lundberg, K., S. Nijenhuis, E. R. Vossenaar, K. Palmblad, W. J. van Venrooij, L. Klareskog, A. J. Zendman, and H. E. Harris. 2005. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res. Ther. 7: R458-R467.
16. Hill, J. A., S. Southwood, A. Sette, A. M. Jevnikar, D. A. Bell, and E. Cairns. 2003. Cutting edge: the conversion of arginine to citrulline allows for a highaffinity peptide interaction with the rheumatoid arthritis-associated HLADRB1p0401 MHC class II molecule. J. Immunol. 171: 538-541.
17. Hill, J. A., D. A. Bell, W. Brintnell, D. Yue, B. Wehrli, A. M. Jevnikar, D. M. Lee, W. Hueber, W. H. Robinson, and E. Cairns. 2008. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J. Exp. Med. 205: 967-979.
18. Moscarello, M. A., D. D. Wood, C. Ackerley, and C. Boulias. 1994. Myelin in multiple sclerosis is developmentally immature. J. Clin. Invest. 94: 146-154.
19. Wood, D. D., J. M. Bilbao, P. O'Connors, and M. A. Moscarello. 1996. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann. Neurol. 40: 18-24.
20. Tranquill, L. R., L. Cao, N. C. Ling, H. Kalbacher, R. M. Martin, and J. N. Whitaker. 2000. Enhanced T cell responsiveness to citrulline-containing myelin basic protein in multiple sclerosis patients. Mult. Scler. 6: 220-225.
21. Cao, L., D. Sun, and J. N. Whitaker. 1998. Citrullinated myelin basic protein induces experimental autoimmune encephalomyelitis in Lewis rats through a diverse T cell repertoire. J. Neuroimmunol. 88: 21-29.
22. Zhou, S. R., M. A. Moscarello, and J. N. Whitaker. 1995. The effects of citrullination or variable amino-terminus acylation on the encephalitogenicity of human myelin basic protein in the PL/J mouse. J. Neuroimmunol. 62: 147-152.
23. Akiyama, K., Y. Sakurai, H. Asou, and T. Senshu. 1999. Localization of peptidylarginine deiminase type II in a stage-specific immature oligodendrocyte from rat cerebral hemisphere. Neurosci. Lett. 274: 53-55.
24. Sambandam, T., M. Belousova, M. A. Accaviti-Loper, C. Blanquicett, V. Guercello, R. Raijmakers, and A. P. Nicholas. 2004. Increased peptidylarginine deiminase type II in hypoxic astrocytes. Biochem. Biophys. Res. Commun. 325: 1324-1329.
25. Nicholas, A. P., T. Sambandam, J. D. Echols, and S. R. Barnum. 2005. Expression of citrullinated proteins in murine experimental autoimmune encephalomyelitis. J. Comp. Neurol. 486: 254-266.
26. Raijmakers, R., J. Vogelzangs, J. L. Croxford, P. Wesseling, W. J. van Venrooij, and G. J. Pruijn. 2005. Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 486: 243-253.
27. Kidd, B. A., P. P. Ho, O. Sharpe, X. Zhao, B. H. Tomooka, J. L. Kanter, L. Steinman, and W. H. Robinson. 2008. Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res. Ther. 10: R119.
28. McGeachy,M. J., L. A. Stephens, and S. M. Anderton. 2005. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 175: 3025-3032.
29. O'Connor, R. A., K. H. Malpass, and S. M. Anderton. 2007. The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells. J. Immunol. 179: 958-966.
30. Sweenie, C. H., K. J. Mackenzie, A. Rone-Orugboh, M. Liu, and S. M. Anderton. 2007. Distinct T cell recognition of naturally processed and cryptic epitopes within the immunodominant 35-55 region of myelin oligodendrocyte glycoprotein. J. Neuroimmunol. 183: 7-16.
31. Mendel, I., N. Kerlero de Rosbo, and A. Ben-Nun. 1995. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol. 25: 1951-1959.
32. Ben-Nun, A., N. Kerlero de Rosbo, N. Kaushansky, M. Eisenstein, L. Cohen, J. F. Kaye, and I. Mendel. 2006. Anatomy of T cell autoimmunity to myelin oligodendrocyte glycoprotein (MOG): prime role of MOG44F in selection and control of MOG-reactive T cells in H-2b mice. Eur. J. Immunol. 36: 478-493.
33. Petersen, T. R., E. Bettelli, J. Sidney, A. Sette, V. Kuchroo, and B. T. Bäckström. 2004. Characterization of MHC- and TCR-binding residues of the myelin oligodendrocyte glycoprotein 38-51 peptide. Eur. J. Immunol. 34: 165-173.
34. Raijmakers, R., J. Vogelzangs, J. Raats, M. Panzenbeck, M. Corby, H. Jiang, M. Thibodeau, N. Haynes, W. J. van Venrooij, G. J. Pruijn, and B. Werneburg. 2006. Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice. J. Comp. Neurol. 498: 217-226.
35. Fazilleau, N., C. Delarasse, C. H. Sweenie, S. M. Anderton, S. Fillatreau, F. A. Lemonnier, D. Pham-Dinh, and J. M. Kanellopoulos. 2006. Persistence of autoreactive myelin oligodendrocyte glycoprotein (MOG)-specific T cell repertoires in MOG-expressing mice. Eur. J. Immunol. 36: 533-543.
36. Hochweller, K., and S. M. Anderton. 2005. Kinetics of costimulatory molecule expression by T cells and dendritic cells during the induction of tolerance versus immunity in vivo. Eur. J. Immunol. 35: 1086-1096.
37. O'Connor, R. A., C. T. Prendergast, C. A. Sabatos, C. W. Lau, M. D. Leech, D. C. Wraith, and S. M. Anderton. 2008. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 181: 3750-3754.
38. McMahon, E. J., S. L. Bailey, C. V. Castenada, H. Waldner, and S. D. Miller. 2005. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11: 335-339.
39. Bailey, S. L., B. Schreiner, E. J. McMahon, and S. D. Miller. 2007. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T (H)-17 cells in relapsing EAE. Nat. Immunol. 8: 172-180.
40. Evavold, B. D., J. Sloan-Lancaster, and P. M. Allen. 1993. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol. Today 14: 602-609.
41. Evavold, B. D., and P. M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252: 1308-1310.
42. Snoke, K., J. Alexander, A. Franco, L. Smith, J. V. Brawley, P. Concannon, H. M. Grey, A. Sette, and P. Wentworth. 1993. The inhibition of different T cell lines specific for the same antigen with TCR antagonist peptides. J. Immunol. 151: 6815-6821.
43. Anderton, S. M., S. Kissler, A. G. Lamont, and D. C. Wraith. 1999. Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells. Eur. J. Immunol. 29: 1850-1857.
44. Kuchroo, V. K., J. M. Greer, D. Kaul, G. Ishioka, A. Franco, A. Sette, R. A. Sobel, and M. B. Lees. 1994. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153: 3326-3336.
45. Margot, C. D., M. L. Ford, and B. D. Evavold. 2005. Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid protein 139-151. J. Immunol. 174: 3352-3358.
46. Leech, M. D., C. Y. Chung, A. Culshaw, and S. M. Anderton. 2007. Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis. Eur. J. Immunol. 37: 3576-3581.
47. Fillatreau, S., C. H. Sweenie, M. J. McGeachy, D. Gray, and S. M. Anderton. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3: 944-950.
48. van Gaalen, F., A. Ioan-Facsinay, T. W. Huizinga, and R. E. Toes. 2005. The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. J. Immunol. 175: 5575-5580.
49. Uysal, H., R. Bockermann, K. S. Nandakumar, B. Sehnert, E. Bajtner, A. Engström, G. Serre, H. Burkhardt, M. M. Thunnissen, and R. Holmdahl. 2009. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J. Exp. Med. 206: 449-462.
50. Molberg, O., S. N. Mcadam, R. Körner, H. Quarsten, C. Kristiansen, L. Madsen, L. Fugger, H. Scott, O. Norén, P. Roepstorff, et al. 1998. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4: 713-717.
51. Arentz-Hansen, H., R. Körner, O. Molberg, H. Quarsten, W. Vader, Y. M. Kooy, K. E. Lundin, F. Koning, P. Roepstorff, L. M. Sollid, and S. N. McAdam. 2000. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J. Exp. Med. 191: 603-612.
52. Corthay, A., J. Bäcklund, J. Broddefalk, E. Michaëlsson, T. J. Goldschmidt, J. Kihlberg, and R. Holmdahl. 1998. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur. J. Immunol. 28: 2580-2590.
53. p molecules. Eur. J. Immunol. 28: 755-767.
54. Bäcklund, J., A. Treschow, R. Bockermann, B. Holm, L. Holm, S. Issazadeh-Navikas, J. Kihlberg, and R. Holmdahl. 2002. Glycosylation of type II collagen is of major importance for T cell tolerance and pathology in collagen-induced arthritis. Eur. J. Immunol. 32: 3776-3784.
55. Bäcklund, J., S. Carlsen, T. Höger, B. Holm, L. Fugger, J. Kihlberg, H. Burkhardt, and R. Holmdahl. 2002. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. [see comment] Proc. Natl. Acad. Sci. USA 99: 9960-9965.
56. Wållberg, M., J. Bergquist, A. Achour, E. Breij, and R. A. Harris. 2007. Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity. Eur. J. Immunol. 37: 1986-1995.
57. Deraos, G., K. Chatzantoni, M. T. Matsoukas, T. Tselios, S. Deraos, M. Katsara, P. Papathanasopoulos, D. Vynios, V. Apostolopoulos, A. Mouzaki, and J. Matsoukas. 2008. Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (MBP(87-99)) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease. J. Med. Chem. 51: 7834-7842.
58. de Haan, E. C., J. P. Wagenaar-Hilbers, R. M. Liskamp, E. E. Moret, and M. H. Wauben. 2005. Limited plasticity in T cell recognition of modified T cell receptor contact residues in MHC class II bound peptides. Mol. Immunol. 42: 355-364.